Dr. Darrin M. Disley OBE - CEO

Dr. Darrin M. Disley OBE

Chief Executive Officer

Darrin is a renowned scientist, entrepreneur, angel investor and enterprise champion who has started, grown, or invested in over 40 start-up life science, technology and social enterprises, raising $600 million USD in business financing and closing $700 million USD in commercial deals. He was CEO of Horizon Discovery Group plc for 11 years, during which he led the Company from start-up through a $113 million USD IPO, and rapid scale-up powered by multiple acquisitions of US peer companies to become a global market leader in gene editing and gene modulation technologies. He was awarded a lifetime Queen’s Award for Enterprise Promotion in 2016 for his work in promoting enterprise across the UK and appointed OBE in 2018 for his services to business and enterprise in the healthcare sector.

Chasing the Holy Grail of Cell Therapy  Labiotech featuring Dr. Darrin M. Disley 

Dr. Louise Modis - CSO

Dr. Louise Modis

Chief Scientific Officer

Louise is an accomplished scientific leader with over 20 years’ experience in pre-clinical and clinical therapeutic research across various modalities and therapeutic areas. Formerly Vice President of Immunology Research at GlaxoSmithKline (GSK), she led the generation and advancement of a pipeline of assets from target identification through to clinical proof-of-concept studies. In her career, Louise has led research teams at Boehringer Ingelheim Pharmaceuticals and Millennium Pharmaceuticals (now Takeda), as well as represented GSK on the board of Sitryx.

Louise completed her PhD in Developmental Hematology at EMBL, Heidelberg, Germany and postdoctoral fellowship at Harvard University, Boston.

The Cell Reprogrammer – The Medicine Maker featuring Dr. Louise Modis

Dr. Karin Schmitt - CBO (Platform Technologies)

Dr. Karin Schmitt

Chief Business Officer (Platform Technologies)

Karin is a globally experienced science and business executive with more than 25 years of diverse experience in biotech drug discovery, platform development and medical device companies. With a recent emphasis on cell and gene therapy, her career spans the Boston area, Silicon Valley and the Cambridge cluster. Karin has been an early employee in several successful start-ups, including Millennium Pharmaceuticals, Exelixis and Horizon Discovery making significant contributions to the rapid growth of these companies to IPO and beyond. Karin obtained her PhD in molecular biology at the University of Southern California in Los Angeles, followed by three years of post-doctoral research in genetics at the University of Cambridge.

Becoming a Successful Leader in the Life Sciences – Technology Networks featuring Dr. Karin Schmitt 

Joe Foster - COO

Joe Foster

Chief Operating Officer

Joe began his career at Horizon Discovery Group plc working within the corporate development team gaining experience in business planning, licensing, technology evaluation and M&A analysis, before becoming Dr. Jonathan Milner’s (Co-founder of Abcam plc) Portfolio Manager where he built and managed a complex portfolio of more than 40 early-stage life science companies. Joe holds a degree in molecular and cellular biology from the University of Bath and an MPhil in business management from the University of Cambridge.

Leading the Movement Towards Direct Cell Conversion – Technology Networks featuring Joe Foster. 

Pierre-Louis Joffrin - CDO

Pierre-Louis Joffrin

Corporate Development Officer

Pierre-Louis has a background in biochemistry and pharmacology from the University of St Andrews and the University of Oxford. He previously worked in early stage venture development and investment at Oxford Sciences Innovations (OSI) and Deep Science Ventures (DSV) before becoming the first employee at Mogrify.

Cell Therapy – Falling short of its potential? – Drug Discovery World featuring Pierre-Louis Joffrin

Prof. Julian Gough - CSA (Bioinformatics)

Prof. Julian Gough

Chief Scientific Advisor (Bioinformatics)

Julian is a biotech entrepreneur and world expert in bioinformatics. He graduated his PhD in molecular biology from the University of Cambridge and was a research fellow at Stanford University. He is now a Programme Leader at the MRC Laboratory of Molecular Biology in Cambridge and Professor of Bioinformatics at the University of Bristol. He has successfully started a number of biotech companies.

Dr. Darrin M. Disley OBE - CEO
Dr. Louise Modis - CSO
Dr. Karin Schmitt - CBO (Platform Technologies)
Joe Foster - COO
Pierre-Louis Joffrin - Corporate Development Officer
Prof. Julian Gough - CSA (Bioinformatics)


Leadership Team